Preclinical results have demonstrated the ability of tyrosine kinase inhibitors (TKIs) to inhibit tumor cell growth, angiogenesis, survival, and proliferation in several different EGFR-transfected GBM cell lines. Here, EGFR is linked to glioblastoma.